Back to News
Market Impact: 0.3
AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The U.S. FDA approved AstraZeneca subsidiary Alexion’s Ultomiris to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. The article provides no sales estimates, trial results, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AZN0.80
More News
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Musk's clash with Ukraine accelerates demand for Starlink alternatives. Few exist
- Trump invokes Cold War era Defense Production Act for oil production, refining
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace